drugset / Trial / NCT00042666
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
NaSingle-groupOpen-labelTreatment
Summary
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
Timeline
- Start
- 2002-06
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | enzastaurin | Small molecule | 500 mg | Oral |